Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 1, 2025

Credo Technology Group Holding Ltd Reports Second Quarter of Fiscal Year 2026 Financial Results

View original at finance.yahoo.com
Credo Technology Group Holding Ltd Reports Second Quarter of Fiscal Year 2026 Financial Results SAN JOSE, Calif., December 01, 2025--(BUSINESS WIRE)--Credo Technology Group Holding Ltd (Credo) (Nasdaq: CRDO), an innovator in providing reliable, energy-efficient, system-level connectivity solutions for the next generati…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • GAAP gross margin is expected to be between 63.8% and 65.8% for Q3 FY2026

    80% confidence
  • In the second quarter Credo delivered revenue of $268.0 million, an increase of 20% sequentially and an extraordinary 272% increase year-over-year

    80% confidence
  • GAAP operating expenses are expected to be between $116.0 million and $120.0 million for Q3 FY2026

    80% confidence
  • The combination of continued growth in core AEC and IC franchises, plus upcoming ramps of ZeroFlap Optics, ALCs, and OmniConnect gearbox solutions gives an outlook with strong revenue growth and profitability through fiscal 2026 and beyond

    80% confidence
  • Revenue is expected to be between $335.0 million and $345.0 million for Q3 FY2026

    80% confidence
  • The results reflect the continued build-out of the world's largest AI training and inference clusters

    80% confidence
  • Non-GAAP operating expenses are expected to be between $68.0 million and $72.0 million for Q3 FY2026

    80% confidence
  • These are the strongest quarterly results in Credo's history

    80% confidence
  • Non-GAAP gross margin is expected to be between 64.0% and 66.0% for Q3 FY2026

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,351 source documents archived
Query this data → isubstrate.com